{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:11:11Z","timestamp":1789506671704,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016469","name":"Takeda Pharmaceuticals International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016469","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.vaccine.2026.128929","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T21:45:48Z","timestamp":1784670348000},"page":"128929","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Beyond neutralization: A comprehensive framework for evaluating humoral immunity induced by a live-attenuated tetravalent dengue vaccine"],"prefix":"10.1016","volume":"88","author":[{"given":"Raphael","family":"Gottardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansi","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo J.M.","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vianney","family":"Tricou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayuri","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128929_bb0005","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(23)02576-X","article-title":"Dengue","volume":"403","author":"Paz-Bailey","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128929_bb0010","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2026.128929_bb0015","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2026.128929_bb0020","doi-asserted-by":"crossref","first-page":"eabm3151","DOI":"10.1126\/scitranslmed.abm3151","article-title":"Antibody fc characteristics and effector functions correlate with protection from symptomatic dengue virus type 3 infection","volume":"14","author":"Dias","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2026.128929_bb0025","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.179771","article-title":"Frequency of dengue virus-specific T cells is related to infection outcome in endemic settings","volume":"10","author":"G\u00e1lvez","year":"2025","journal-title":"JCI Insight"},{"key":"10.1016\/j.vaccine.2026.128929_bb0030","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.3390\/v14112575","article-title":"Immune-mediated pathogenesis in dengue virus infection","volume":"14","author":"Khanam","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2026.128929_bb0035","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41577-019-0123-x","article-title":"Adaptive immune responses to primary and secondary dengue virus infections","volume":"19","author":"St. John","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2026.128929_bb0040","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1016\/S1473-3099(16)30473-X","article-title":"Dengue: knowledge gaps, unmet needs, and research priorities","volume":"17","author":"Katzelnick","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128929_bb0045","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1186\/s12964-024-01779-4","article-title":"Immunomodulation in dengue: towards deciphering dengue severity markers","volume":"22","author":"Dash","year":"2024","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.vaccine.2026.128929_bb0050","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3389\/fimmu.2015.00238","article-title":"Mast cells and influenza a virus: association with allergic responses and beyond","volume":"6","author":"Graham","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128929_bb0055","author":"World Health Organization"},{"key":"10.1016\/j.vaccine.2026.128929_bb0060","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1093\/infdis\/jiac476","article-title":"Antibodies produced in response to a live-attenuated dengue vaccine are functional in activating the complement system","volume":"227","author":"Nascimento","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128929_bb0065","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/infdis\/jiab064","article-title":"Development of a novel assay to assess the avidity of dengue virus-specific antibodies elicited in response to a tetravalent dengue vaccine","volume":"225","author":"Tsuji","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128929_bb0070","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/infdis\/jiz081","article-title":"Magnitude and functionality of the NS1-specific antibody response elicited by a live-attenuated tetravalent dengue vaccine candidate","volume":"221","author":"Sharma","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128929_bb0075","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1016\/j.vaccine.2017.07.045","article-title":"Participants in the Summit on Dengue Immune Correlates of Protection. Immune correlates of protection for dengue: state of the art and research agenda","volume":"35","author":"Katzelnick","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128929_bb0080","author":"European Medicine Evaluations Agency"},{"key":"10.1016\/j.vaccine.2026.128929_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002243","article-title":"Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax)","volume":"7","author":"Huang","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2026.128929_bb0090","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(20)30414-1","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children aged 4\u201316 years: a randomised, placebo-controlled, phase 3 trial","volume":"395","author":"Biswal","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128929_bb0095","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1903869","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children and adolescents","volume":"381","author":"Biswal","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128929_bb0100","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1016\/S2214-109X(23)00522-3","article-title":"Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4\u00b75-year results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"12","author":"Tricou","year":"2024","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2026.128929_bb0105","series-title":"Presented at: 14th World Congress of the World Society for Pediatric Infectious Diseases; Bangkok, Thailand; October 28\u201331","article-title":"Evaluation of booster dose of the tetravalent dengue vaccine TAK-003 in healthy children in dengue endemic regions (DEN-301)","author":"Escudero","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128929_bb0110","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1473-3099(25)00382-2","article-title":"Effectiveness of the TAK-003 dengue vaccine in adolescents during the 2024 outbreak in S\u00e3o Paulo, Brazil: a test-negative, case\u2013control study","volume":"1","author":"Ranzani","year":"2026","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128929_bb0115","unstructured":"Ministerio de Salud. Vacunaci\u00f3n contra el dengue: proceso de an\u00e1lisis para la implementaci\u00f3n como estrategia integrada de salud p\u00fablica. https:\/\/www.argentina.gob.ar\/sites\/default\/files\/2024\/03\/conain_presentacion_07-03-2024.pdf; 2024, [accessed 27 September 2024]."},{"key":"10.1016\/j.vaccine.2026.128929_bb0120","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1473-3099(17)30632-1","article-title":"Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study","volume":"18","author":"S\u00e1ez-Llorens","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128929_bb0125","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1473-3099(17)30166-4","article-title":"Safety and immunogenicity of one versus two doses of Takeda\u2019s tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study","volume":"17","author":"S\u00e1ez-Llorens","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128929_bb0130","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0140-6736(20)30556-0","article-title":"Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2-17 years: a randomised, placebo-controlled, phase 2 trial","volume":"395","author":"Tricou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128929_bb0135","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1093\/infdis\/jiac272","article-title":"Specificity and breadth of the neutralizing antibody response to a live-attenuated tetravalent dengue vaccine","volume":"226","author":"DeMaso","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128929_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222112004","article-title":"Development and characterization of a multiplex assay to quantify complement-fixing antibodies against dengue virus","volume":"22","author":"Nascimento","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.vaccine.2026.128929_bb0145","series-title":"Guidelines for plaque reduction neutralization testing of human antibodies to dengue viruses","author":"World Health Organization","year":"2007"},{"key":"10.1016\/j.vaccine.2026.128929_bb0150","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1473-3099(14)70811-4","article-title":"Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study","volume":"14","author":"Osorio","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128929_bb0155","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41541-023-00658-2","article-title":"Is new dengue vaccine efficacy data a relief or cause for concern?","volume":"8","author":"Thomas","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2026.128929_bb0160","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41573-022-00495-3","article-title":"Antibodies to combat viral infections: development strategies and progress","volume":"21","author":"Pantaleo","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.vaccine.2026.128929_bb0165","article-title":"From antibodies to immunity: assessing correlates of flavivirus protection and cross-reactivity","volume":"13","author":"Flores","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128929_bb0170","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1093\/infdis\/jiae505","article-title":"Systems vaccinology: navigating the future of personalized immunity and next-generation vaccines","volume":"230","author":"Dib","year":"2024","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128929_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075665","article-title":"Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial","volume":"8","author":"Gottardo","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2026.128929_bb0180","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nri2629","article-title":"Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology","volume":"9","author":"Pulendran","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2026.128929_bb0185","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1093\/infdis\/jiaf171","article-title":"Anti-dengue virus antibody avidity correlates with protection against symptomatic dengue virus infection","volume":"232","author":"Tsuji","year":"2025","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128929_bb0190","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1080\/14760584.2025.2490295","article-title":"TAK-003: development of a tetravalent dengue vaccine","volume":"24","author":"S\u00e1ez-Llorens","year":"2025","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.128929_bb0195","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2100","article-title":"The role of anti-flavivirus humoral immune response in protection and pathogenesis","volume":"30","author":"Hurtado-Monz\u00f3n","year":"2020","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.vaccine.2026.128929_bb0200","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: from structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128929_bb0205","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.3389\/fimmu.2019.01276","article-title":"Approaches to interrogating the human memory B-cell and memory-derived antibody repertoire following dengue virus infection","volume":"10","author":"Lyski","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128929_bb0210","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/infdis\/jiaa346","article-title":"Characterization of the type-specific and cross-reactive B-cell responses elicited by a live-attenuated tetravalent dengue vaccine","volume":"223","author":"Michlmayr","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128929_bb0215","series-title":"Immunobiology: The immune system in health and disease","article-title":"The distribution and functions of immunoglobulin isotypes","author":"Janeway","year":"2001"},{"key":"10.1016\/j.vaccine.2026.128929_bb0220","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/cid\/ciae369","article-title":"Immunogenicity, safety, and efficacy of a tetravalent dengue vaccine in children and adolescents: an analysis by age group","volume":"80","author":"Borja-Tabora","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128929_bb0225","doi-asserted-by":"crossref","first-page":"6999","DOI":"10.1016\/j.vaccine.2023.09.049","article-title":"Consistency of immunogenicity in three consecutive lots of a tetravalent dengue vaccine candidate (TAK-003): a randomized placebo-controlled trial in US adults","volume":"41","author":"Tricou","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128929_bb0230","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S1473-3099(22)00801-5","article-title":"Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression","volume":"23","author":"Bobrovitz","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128929_bb0235","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/infdis\/jiac482","article-title":"Persistence of immunogenicity of a purified inactivated Zika virus vaccine candidate in healthy adults: 2 years of follow-up compared with natural infection","volume":"227","author":"Acosta","year":"2023","journal-title":"J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26007383?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26007383?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:35:49Z","timestamp":1789504549000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26007383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":47,"alternative-id":["S0264410X26007383"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128929","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond neutralization: A comprehensive framework for evaluating humoral immunity induced by a live-attenuated tetravalent dengue vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128929","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128929"}}